🇺🇸 FDA
Pipeline program

Effect of NBI-921355 on corticospinal excitability in healthy participants

NBI-921355-1785

Phase 1 other active

Quick answer

Effect of NBI-921355 on corticospinal excitability in healthy participants for Epilepsy is a Phase 1 program (other) at NEUROCRINE BIOSCIENCES INC with 1 ClinicalTrials.gov record(s).

Program details

Company
NEUROCRINE BIOSCIENCES INC
Indication
Epilepsy
Phase
Phase 1
Modality
other
Status
active

Clinical trials